July 31, 2007 - GlaxoSmithKline announced the recommendation of an FDA advisory committee to support Avandia’s (rosiglitazone maleate), an oral anti-diabetic medicine, continued availability to patients in the U.S., information which the FDA will consider its final decision-making process.
